Aerovate Therapeutics shares dropped 90.4% following the release of Phase 2b trial results for AV-101 for pulmonary arterial hypertension. Despite being well tolerated, AV-101 failed to meet primary and secondary endpoints. Enrollment for Phase 3 is halted.
U.S. stocks were higher, with the Nasdaq Composite gaining over 100 points on Friday.
Shares of Ermenegildo Zegna N.V. (NYSE: ZGN) fell sharply during Friday’s session as the company reported FY23 financial results.
Aerovate Therapeutics, Inc. (NASDAQ:AVTE), a clinical stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease, today announced an upcoming poster